List of Excipients in Branded Drug FOSPHENYTOIN

Generic Drugs Containing FOSPHENYTOIN

Company	Ingredient	NDC	Excipient
Fresenius Kabi USA LLC	fosphenytoin sodium	63323-403	HYDROCHLORIC ACID
Fresenius Kabi USA LLC	fosphenytoin sodium	63323-403	SODIUM HYDROXIDE
Fresenius Kabi USA LLC	fosphenytoin sodium	63323-403	TROMETHAMINE
Fresenius Kabi USA LLC	fosphenytoin sodium	63323-403	WATER

What are the Most Frequently-Used Excipients in FOSPHENYTOIN?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
1	SODIUM HYDROXIDE
1	TROMETHAMINE
1	WATER

Fosphenytoin Excipient Strategy and Commercial Opportunities

Last updated: October 2, 2026

Fosphenytoin is an injectable phosphate prodrug of phenytoin used for rapid parenteral loading in status epilepticus and when oral phenytoin is impractical. Its commercial value is concentrated in hospital emergency care, where excipient design can improve preparation time, dilution flexibility, container compatibility, shelf life, and administration safety. The strongest opportunities are ready-to-use presentations, pediatric and prehospital formats, and differentiated stability or device combinations rather than new systemic pharmacology.

What excipients are used in fosphenytoin injection?

Fosphenytoin injection uses a relatively simple aqueous formulation. The reference product, Cerebyx, contains fosphenytoin sodium, tromethamine buffer, hydrochloric acid and sodium hydroxide for pH adjustment, and Water for Injection. The labeled pH is approximately 8.6 to 9.0. The product is supplied as a sterile, preservative-free solution. [1]

Formulation element	Function	Commercial implication
Fosphenytoin sodium	Phosphate prodrug active ingredient	Provides water solubility and avoids the organic solvent system used in injectable phenytoin
Tromethamine	Buffer and pH-control agent	Supports solution stability and solubility at alkaline pH
Hydrochloric acid and sodium hydroxide	pH adjustment	Critical to maintaining the intended formulation range
Water for Injection	Vehicle	Standard parenteral solvent
No antimicrobial preservative	Supports single-dose sterile use	Favors vial, syringe, or premixed bag formats over multidose containers

The formulation advantage over phenytoin is the absence of propylene glycol and ethanol as primary solubilizing agents. Injectable phenytoin has been associated with formulation-related concerns including local tissue injury, hypotension, cardiac effects, and precipitation risk. Fosphenytoin was developed to provide a more practical parenteral alternative, although it retains dose, infusion-rate, and cardiovascular monitoring requirements. [1,2]

How does fosphenytoin excipient design differ from phenytoin?

Fosphenytoin and phenytoin require different formulation strategies because their aqueous solubility profiles are materially different.

Attribute	Fosphenytoin injection	Phenytoin injection
Chemical form	Phosphate prodrug	Active hydantoin
Primary formulation vehicle	Water for Injection	Water with organic cosolvents
Typical pH	Alkaline, approximately 8.6-9.0	Strongly alkaline
Key solubilization issue	Maintaining phosphate-prodrug stability and solution clarity	Maintaining phenytoin solubility
Common excipient concern	Buffer capacity, degradation, compatibility	Precipitation, tissue irritation, solvent exposure
Infusion handling	Can be diluted in compatible IV solutions	More restrictive administration profile
Excipient differentiation potential	High for ready-to-use and stability formats	More constrained by solvent and precipitation requirements

Fosphenytoin’s phosphate group improves aqueous handling but introduces new formulation risks. These include hydrolysis, pH-dependent degradation, phosphate-related compatibility concerns, and possible interactions with calcium-containing or other multivalent-cation solutions. Product development should evaluate the active phosphate prodrug, released phosphate species, and phenytoin formation over the full shelf life and in-use period.

What excipient strategies offer the strongest commercial opportunities?

Ready-to-use intravenous bags

The most commercially direct opportunity is a premixed, ready-to-administer infusion bag. Current hospital use commonly involves withdrawal from a vial, dilution, labeling, and administration within institutional procedures. A validated premixed presentation could reduce preparation steps and medication-error exposure.

Potential presentations include:

• Low-dose pediatric bags
• Standard adult loading-dose bags
• Small-volume emergency bags
• Pharmacy-ready presentations with barcoded overwraps
• Dual-volume formats for emergency departments and intensive-care units

The formulation would need to demonstrate chemical stability, sterility, container compatibility, and acceptable particulate performance during storage and administration. The development program should compare polyolefin, multilayer, and other parenteral bag systems, because adsorption, permeability, extractables, and leachables can differ by container.

A premixed product may qualify for an abbreviated regulatory pathway if it remains within the same active ingredient, route, dosage form, and therapeutic purpose as an approved reference product. A materially different container, concentration, or administration system can create additional comparative requirements.

Ready-to-use prefilled syringes

A prefilled syringe could target emergency departments, ambulances, military medicine, and procedural settings. Its commercial value would come from eliminating vial withdrawal and reducing dose-calculation steps.

The main technical barriers are:

• Long-term stability in the syringe barrel
• Plunger and stopper compatibility at alkaline pH
• Silicone oil and particulate control
• Dose-volume accuracy
• Sterilization and terminal-processing limitations
• Device extractables and leachables
• Compatibility with needle-free connectors and infusion pumps

Fosphenytoin concentrations are often expressed as phenytoin equivalents, or PE. A prefilled syringe would need prominent labeling to prevent confusion between fosphenytoin sodium mass and phenytoin-equivalent dose. The product should not rely on a small-label distinction between “mg PE” and milligrams of drug substance.

Pediatric and neonatal presentations

Pediatric status epilepticus is a strong segment for excipient and packaging differentiation. Smaller volumes and weight-based dosing increase the risk of calculation and withdrawal errors. Commercial formats could include lower-fill-volume syringes, weight-banded presentations, or dose-specific emergency kits.

Pediatric development would require close review of:

• Dose-volume accuracy at low withdrawals
• Osmolality and pH
• Latex status
• Preservative absence
• Syringe dead space
• Compatibility with pediatric vascular access devices
• In-use stability after partial withdrawal

Neonatal use would require a separate safety and formulation assessment. A formulation acceptable for adults cannot automatically be positioned for neonates based only on the absence of preservatives.

Extended post-dilution stability

An excipient and packaging program could seek longer validated stability after dilution in sodium chloride or dextrose solutions. This has operational value for hospital pharmacies that prepare doses in advance or manage surge conditions.

The study package should include:

• Multiple concentrations across the clinical dilution range
• Both sodium chloride and dextrose vehicles
• Refrigerated and room-temperature conditions
• Light exposure
• Low- and high-surface-area containers
• Simulated administration through common infusion sets
• Assay, degradants, pH, appearance, particulates, and potency

The commercial claim should be based on validated conditions, not on a general statement that fosphenytoin is “compatible” with a diluent.

What formulation patents could protect a fosphenytoin product?

The original active-ingredient and prodrug protection for fosphenytoin is expected to be expired. Commercial protection is more likely to arise from formulation, presentation, device, manufacturing, or use claims than from the molecule itself.

Potential claim categories include:

Claim area	Potential protected subject matter
Premixed solution	Concentration, buffer system, pH range, diluent, and storage period
Prefilled syringe	Drug-container combination, stopper, barrel, lubricant, and stability profile
Ready-to-use bag	Container material, fill volume, oxygen control, and administration conditions
Pediatric product	Dose-banded presentation, low-volume configuration, or administration kit
Manufacturing	Control of phosphate-related impurities, degradation products, or sterilization conditions
Compatibility	Stability through defined connectors, tubing, filters, or infusion devices
Method of use	Emergency administration protocol or specific patient population
Packaging	Light-protective, oxygen-barrier, or tamper-evident configuration

A formulation patent must provide more than a routine substitution of one pharmaceutically acceptable excipient for another. Patent strength would improve if the formulation demonstrated an unexpected stability advantage, reduced impurity formation, improved container compatibility, or a clinically relevant handling benefit.

When does fosphenytoin lose exclusivity?

Fosphenytoin’s original small-molecule exclusivity and core patent protection are no longer the main barriers to entry. The market is generally accessible to approved generic injectable manufacturers, subject to FDA quality, bioequivalence, sterility, and manufacturing requirements.

Exclusivity category	Fosphenytoin position
New chemical entity exclusivity	Expired
Core compound or prodrug patent	Expected to be expired
Biologic exclusivity	Not applicable
Biosimilar pathway	Not applicable
Generic pathway	Primarily ANDA-based for equivalent injectable products
Reformulated product pathway	May involve 505(b)(2), depending on the change
Current commercial moat	Manufacturing reliability, hospital contracting, presentation, and supply continuity

The FDA Orange Book should be reviewed for current listed patents and exclusivity entries associated with each approved fosphenytoin product. Product-specific listings can change, and an Orange Book review should distinguish expired patents from live formulation or method-of-use claims. [3]

What is the FDA regulatory status of fosphenytoin?

FDA-approved fosphenytoin injection is indicated for:

• Treatment of generalized convulsive status epilepticus
• Prevention and treatment of seizures occurring during neurosurgery
• Short-term parenteral substitution for oral phenytoin when oral administration is not possible

The reference labeling uses phenytoin equivalents for dosing. The maximum adult infusion rate is 150 mg PE per minute. Pediatric administration uses a weight-based rate, subject to the labeled maximum. Blood pressure, respiratory status, and cardiac rhythm require monitoring during administration because rapid loading can produce hypotension or arrhythmias. [1]

The regulatory distinction between a conventional generic and a differentiated product is important:

• A conventional equivalent injectable may pursue an ANDA.
• A new concentration, delivery device, or formulation may require additional comparative data.
• A product using a novel excipient at a new parenteral exposure level may face a more extensive safety assessment.
• A new route, indication, or clinically meaningful dosing modification may require a 505(b)(2) application or a full development program.

Are Paragraph IV challenges and biosimilar risks relevant?

Paragraph IV litigation is relevant only where an applicant challenges an unexpired listed patent in the Orange Book. Because the core fosphenytoin estate is mature, the greater risk is product-specific litigation involving later formulation, device, or method-of-use patents.

Biosimilar risk is not relevant. Fosphenytoin is a chemically synthesized small molecule, not a biologic. Competitive threats come from generic injectable manufacturers, contract manufacturing organizations, hospital-compounded alternatives where permitted, and differentiated delivery products.

A generic applicant’s practical barriers are more likely to involve:

• Sterile manufacturing capacity
• Low-volume hospital economics
• Supply-chain reliability
• Container-closure qualification
• Drug-shortage risk
• Validation of dilution and administration compatibility
• Hospital formulary access

Which companies are competing in fosphenytoin?

The competitive field includes the original Cerebyx franchise, approved generic manufacturers, injectable specialty companies, and contract manufacturers capable of producing sterile phosphate-containing solutions. The commercial market is procurement-driven. Hospitals often select products based on availability, price, service levels, shortage history, and electronic medication-system integration.

A new entrant would need to compete against established generic pricing while offering a measurable operational advantage. The most defensible differentiators are:

1. A ready-to-use presentation that reduces pharmacy preparation.
2. A pediatric or weight-banded product that lowers dosing risk.
3. A validated extended in-use stability profile.
4. A device-compatible syringe or bag that fits emergency workflows.
5. Reliable supply during shortages or manufacturing disruptions.

What manufacturing and IP barriers affect fosphenytoin?

Fosphenytoin manufacturing requires tight control of pH, phosphate-related impurities, solution clarity, particulate matter, sterility, and container closure. The alkaline formulation can place demands on elastomers, lubricants, and packaging materials. A formulation that is chemically acceptable in a glass vial may behave differently in a polymer syringe or infusion bag.

Critical development controls include:

• Raw-material control for tromethamine and phosphate-related impurities
• pH adjustment reproducibility
• Assay of fosphenytoin and phenytoin degradant
• Subvisible particulate testing
• Container-closure integrity
• Extractables and leachables
• Light and oxygen exposure
• Freeze-thaw evaluation
• In-use stability after dilution
• Compatibility with administration sets and filters

These controls can create practical barriers even when patent protection is weak. A company that develops a robust formulation and qualifies multiple container systems may have a stronger commercial position than a company relying only on a low-cost vial.

How strong is the commercial opportunity?

The opportunity is moderate for a conventional generic and stronger for a workflow-oriented product. Fosphenytoin is used in acute hospital settings, but the addressable volume is limited by the episodic nature of status epilepticus and the availability of oral phenytoin and alternative antiseizure medicines.

Revenue exposure is concentrated in institutional channels:

• Emergency departments
• Intensive-care units
• Operating rooms
• Neurology services
• Pediatric hospitals
• Ambulance and transport systems
• Government and military procurement

A vial-only entrant would face price competition. A premixed bag, prefilled syringe, or pediatric kit could support a higher price if it demonstrates reduced preparation time, lower error risk, and dependable supply. Commercial adoption would depend on purchasing contracts, pharmacy-and-therapeutics review, barcode integration, and inclusion in emergency medication protocols.

Key Takeaways

• Fosphenytoin uses a simple aqueous, alkaline, preservative-free formulation based on tromethamine, pH adjustment, and Water for Injection.
• Its principal formulation advantage over phenytoin is the absence of the organic cosolvent system used to solubilize injectable phenytoin.
• The strongest commercial opportunities are ready-to-use bags, prefilled syringes, pediatric formats, and extended post-dilution stability.
• Core fosphenytoin exclusivity is mature; formulation, device, manufacturing, and packaging claims offer the more relevant IP opportunities.
• Biosimilar competition does not apply. Generic injectable competition is the principal market threat.
• Product success depends more on sterile manufacturing, container compatibility, hospital workflow, and supply reliability than on active-ingredient exclusivity.
• Any reformulated product must address alkaline pH, phosphate-related degradation, particulates, extractables and leachables, and dose labeling in phenytoin equivalents.

FAQs

Can fosphenytoin be formulated without tromethamine?

A tromethamine-free formulation may be possible, but it would require proof that the alternative buffer or pH-control system maintains solubility, potency, impurity limits, and container compatibility throughout shelf life. Tromethamine substitution is not automatically a clinically or regulatorily neutral change.

Is a fosphenytoin premixed infusion bag patentable?

A premixed bag can support patent claims if its concentration, buffer system, container, stability profile, or administration conditions produce a non-obvious technical advantage. A routine dilution of an approved vial may provide weak patent protection.

Does fosphenytoin require a preservative?

Approved single-dose fosphenytoin injection is preservative-free. A multidose product would require a separate microbiological and toxicological assessment and may be commercially less attractive for emergency hospital use.

Can fosphenytoin be supplied in a prefilled syringe?

Yes, but the syringe system must be qualified for alkaline pH, long-term chemical stability, particulate control, stopper compatibility, and accurate dosing in phenytoin equivalents. Device-specific regulatory data would be required.

What is the most defensible fosphenytoin product strategy?

A pediatric- and emergency-focused ready-to-use presentation with validated stability, clear PE-based dosing, barcode integration, and reliable hospital supply provides the strongest combination of commercial differentiation and formulation-based protection.

References

1. U.S. Food and Drug Administration. (2023). Cerebyx (fosphenytoin sodium) injection prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Dilantin (phenytoin sodium) injection prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.